REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.

• Develops biologic therapies targeting areas such as immunology, oncology, and ophthalmology.

• Uses proprietary antibody and genetic discovery technologies to develop new treatments.

• Commercializes approved medicines across multiple therapeutic categories.

• Maintains global partnerships for research, development, and commercialization.

• Invests heavily in research and development to expand its pipeline of biologic drugs.

Regeneron’s portfolio includes therapies used to treat conditions such as eye diseases, inflammatory disorders, cancer, and infectious diseases. Many of its treatments are based on monoclonal antibody technology developed through the company’s proprietary research platforms.

The company operates research laboratories, clinical development programs, and biopharmaceutical manufacturing facilities that support both approved medicines and pipeline therapies. Its products are distributed globally through a combination of direct commercialization and strategic partnerships.

Regeneron Pharmaceuticals, Inc. is listed on the Nasdaq under the ticker REGN.

History and Development

Regeneron was founded in 1988 in Tarrytown, New York, by Leonard Schleifer and George Yancopoulos with the goal of applying advances in molecular biology and genetics to develop new medicines.

In its early years, the company focused heavily on foundational scientific research, building proprietary technologies designed to accelerate the discovery of antibody-based therapies.

As its research capabilities expanded, Regeneron developed treatments across several therapeutic areas and established collaborations with major pharmaceutical companies to support global development and commercialization.

Today, Regeneron is recognized as one of the leading biotechnology companies in the United States, with a portfolio of approved medicines and an extensive pipeline of biologic therapies under development.

Additional Information

Regeneron Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $65.49 Billions, with shareholders equity totaling $31.42 Billions.

The company employs approximately 9.123 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Regeneron Pharmaceuticals Inc. reported $14.92 Billions in revenue, generating net income of $4.42 Billions.

Key financial metrics include a P/E ratio of 14.80, a price-to-book (P/B) ratio of 2.08, and a trailing twelve-month dividend yield of 0.57%.

The company trades under the ticker REGN.